AMLX (Amylyx Pharmaceuticals, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by AMLX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Karen Firestone | Director | M | — | — |
| 2026-08-20 | Justin B. Klee | Co-Chief Executive Officer | A | — | — |
| 2026-08-20 | Camille L Bedrosian | Chief Medical Officer | A | — | — |
| 2026-08-20 | Joshua B Cohen | Co-Chief Executive Officer | A | — | — |
| 2026-08-20 | Gina Mazzariello | Chief Legal Officer | A | — | — |
| 2026-08-20 | JAMES M FRATES | Chief Financial Officer | A | — | — |
| 2026-07-13 | Gina Mazzariello | Chief Legal Officer | Sell | — | — |
| 2026-06-08 | GEORGE M MILNE JR | Director | A | — | — |
| 2026-06-08 | Bernhardt G Zeiher | Director | A | — | — |
| 2026-06-08 | Karen Firestone | Director | A | — | — |
| 2026-06-08 | PAUL R. FONTEYNE | Director | A | — | — |
| 2026-06-08 | Daphne Quimi | Director | A | — | — |
| 2026-05-26 | Karen Firestone | Director | Buy | — | — |
| 2026-03-09 | Justin B. Klee | Co-Chief Executive Officer | A | — | — |
| 2026-03-09 | Camille L Bedrosian | Chief Medical Officer | A | — | — |
| 2026-03-09 | Gina Mazzariello | Chief Legal Officer | A | — | — |
| 2026-03-09 | Joshua B Cohen | Co-Chief Executive Officer | A | — | — |
| 2026-03-09 | JAMES M FRATES | Chief Financial Officer | A | — | — |
| 2026-03-04 | Camille L Bedrosian | Chief Medical Officer | Sell | — | — |
| 2026-03-04 | JAMES M FRATES | Chief Financial Officer | Sell | — | — |
| 2026-03-04 | Joshua B Cohen | Co-Chief Executive Officer | Sell | — | — |
| 2026-03-04 | Gina Mazzariello | Chief Legal Officer | Sell | — | — |
| 2026-03-04 | Justin B. Klee | Co-Chief Executive Officer | Sell | — | — |
| 2026-02-25 | Gina Mazzariello | Chief Legal Officer | Sell | — | — |
| 2026-02-04 | Joshua B Cohen | Co-Chief Executive Officer | Sell | — | — |
| 2026-02-04 | Justin B. Klee | Co-Chief Executive Officer | Sell | — | — |
| 2026-02-04 | Gina Mazzariello | Chief Legal Officer | Sell | — | — |
| 2026-02-04 | JAMES M FRATES | Chief Financial Officer | Sell | — | — |
| 2026-01-20 | Joshua B Cohen | Co-Chief Executive Officer | MIXED | — | — |
| 2026-01-20 | Justin B. Klee | Co-Chief Executive Officer | MIXED | — | — |
| 2026-01-14 | GEORGE M MILNE JR | Director | G | — | — |
| 2026-01-08 | Joshua B Cohen | Co-Chief Executive Officer | Sell | — | — |
| 2026-01-08 | JAMES M FRATES | Chief Financial Officer | Sell | — | — |
| 2026-01-08 | Justin B. Klee | Co-Chief Executive Officer | Sell | — | — |
| 2025-12-23 | Karen Firestone | Director | Buy | — | — |
| 2025-12-03 | Camille L Bedrosian | Chief Medical Officer | Sell | — | — |
| 2025-10-02 | Camille L Bedrosian | Chief Medical Officer | Sell | — | — |
| 2025-10-02 | Justin B. Klee | Co-Chief Executive Officer | Sell | — | — |
| 2025-10-02 | Gina Mazzariello | Chief Legal Officer | Sell | — | — |
| 2025-10-02 | Joshua B Cohen | Co-Chief Executive Officer | Sell | — | — |
| 2025-10-02 | JAMES M FRATES | Chief Financial Officer | Sell | — | — |
| 2025-08-14 | Gina Mazzariello | Chief Legal Officer | Sell | — | — |
| 2025-06-09 | PAUL R. FONTEYNE | Director | A | — | — |
| 2025-06-09 | GEORGE M MILNE JR | Director | A | — | — |
| 2025-06-09 | Bernhardt G Zeiher | Director | A | — | — |
| 2025-06-09 | Daphne Quimi | Director | A | — | — |
| 2025-06-09 | Karen Firestone | Director | A | — | — |
| 2025-05-27 | Gina Mazzariello | Chief Legal Officer | G | — | — |
| 2025-04-02 | JAMES M FRATES | Chief Financial Officer | Sell | — | — |
| 2025-04-02 | Gina Mazzariello | Chief Legal Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 10,678,808 | — |
| — | 10%+ Owner | 5,897,587 | — |
| — | 10%+ Owner | 4,997,302 | — |
| — | 10%+ Owner | 4,870,536 | — |
| — | 10%+ Owner | 4,082,713 | — |
| — | Co-Chief Executive Officer | 3,643,587 | — |
| — | Co-Chief Executive Officer | 3,643,520 | — |
| — | Director | 1,415,613 | — |
| — | Director | 812,881 | — |
| — | Chief Medical Officer | 288,092 | — |
| — | Chief Commercial Officer | 276,108 | — |
| — | Chief Financial Officer | 255,507 | — |
| — | Chief Medical Officer | 205,605 | — |
| — | Chief Legal Officer | 200,374 | — |
| — | Director | 91,900 | — |
| — | Director | 10,000 | — |
| — | Director | 3,947 | — |
| — | Director | 2,750 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AMLX quote page; the site-wide leaderboard is on the insider transactions hub.